Omnicell, Inc.
NASDAQ:OMCLMedical - Healthcare Information Services
-$0.58 today
- Market cap
- $1.59B
- Beta
- 0.96
- P/E (TTM)
- 84.1
- EPS (TTM)
- $0.45
Volume 0.34M
Average 0.57M
OMCL Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Omnicell, Inc.NASDAQ: OMCL
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 5.0% from a year ago
Net receivables stood at $264.21M at the end of Q1 FY2026, up 5.0% from a year earlier and up 21.8% from the prior quarter. Over 3 fiscal years it compounded at -10.2% a year.
Context
- Net receivables amounted to 13.2% of total assets at the end of Q1 FY2026, up 1.5 pp from a year earlier.
- Net receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +5.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 216.86M USD
- Year-over-year change
- -15.4%
- 4-year CAGR
- -2.6%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 216.86M | -15.4% |
| FY2024 | 2024-12-31 | 256.4M | -2.8% |
| FY2023 | 2023-12-31 | 263.89M | -11.9% |
| FY2022 | 2022-12-31 | 299.47M | +24.3% |
| FY2021 | 2021-12-31 | 240.89M | — |
Net Receivables vs competitors
How OMCL compares with its peers on the latest reported figures
- OMCL's Mar 2026 net receivables of $264.21M is the 2nd highest of the 11 companies compared; the peer median is $130.34M.
- Its year-over-year change of +5.0% is the 7th highest of 11, against a peer median of +34.0%.
- Net receivables amounts to 13.2% of total assets for OMCL, versus a peer median of 15.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $500.07M | +52.2% | +50.4% | 21.2% | |
| Mar 2026 | $264.21M | +5.0% | -10.2% | 13.2% | |
| Jun 2026 | $257.48M | -5.3% | -2.8% | 36.0% | |
| Mar 2026 | $244.62M | +42.2% | +28.0% | 12.1% | |
| Mar 2026 | $222.54M | -8.5% | -5.1% | 7.9% | |
| Apr 2026 | $143.31M | +32.6% | +44.4% | 21.5% | |
| Jun 2026 | $117.37M | +35.5% | +17.0% | 17.2% | |
| Sep 2026 | $58.76M | -39.2% | -7.5% | 5.5% | |
| Sep 2026 | $48.36M | -15.7% | +14.7% | 7.9% | |
| Mar 2026 | $39.99M | +36.6% | +43.7% | 13.2% | |
| Mar 2026 | $21.32M | +165.1% | +70.7% | 23.5% | |
| Peer median (excluding OMCL) | $130.34M | +34.0% | +22.5% | 15.2% | |
Competitors are the stored peer set for OMCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 349.05M | 330.36M | 467.97M | 369.2M | 196.52M |
| Short-term Investments | 10.67M | 11.49M | 0 | 12.48M | 0 |
| Net Receivables | 240.89M | 299.47M | 263.89M | 256.4M | 216.86M |
| Inventory | 119.92M | 147.55M | 110.1M | 88.66M | 100.91M |
| Other Current Assets | 31.01M | 64.17M | 51.36M | 61.48M | 132.08M |
| Total Current Assets | 780.7M | 881.81M | 927.57M | 815.49M | 680.07M |
| Property, Plant & Equipment (Net) | 119.69M | 132.01M | 133.59M | 138.3M | 144.48M |
| Goodwill | 738.9M | 734.27M | 735.81M | 734.73M | 737.95M |
| Intangible Assets | 374.61M | 323.67M | 277.83M | 246.7M | 170.11M |
| Long-term Investments | 18.39M | 32.92M | 54.8M | 52.74M | 60.74M |
| Tax Assets | 15.88M | 22.33M | 32.9M | 57.47M | 58.34M |
| Other Non-current Assets | 94.32M | 83.74M | 64.37M | 75.53M | 123.04M |
| Total Non-current Assets | 1.36B | 1.33B | 1.3B | 1.31B | 1.29B |
| Total Assets | 2.14B | 2.21B | 2.23B | 2.12B | 1.97B |
| Account Payables | 71.51M | 63.39M | 45.03M | 51.78M | 43.99M |
| Short-term Debt | 488.15M | 0 | 0 | 174.32M | 0 |
| Tax Payables | 3.77M | 9.64M | 2.19M | 11.44M | 0 |
| Deferred Revenue | 152.11M | 187.21M | 132.29M | 201.98M | 283.48M |
| Other Current Liabilities | 71.13M | 73.46M | 126.02M | 60.31M | 57.17M |
| Total Current Liabilities | 876.16M | 428.45M | 367.79M | 595.68M | 476.61M |
| Long-term Debt | 0 | 566.57M | 569.66M | 166.4M | 167.6M |
| Deferred Tax Liabilities | 51.71M | 2.1M | 1.62M | 1.11M | 683K |
| Deferred Revenue (Non-current) | 20.19M | 37.39M | 58.62M | 76.12M | 63.25M |
| Other Non-current Liabilities | 7.84M | 6.72M | 6.32M | 7.22M | 9.97M |
| Total Non-current Liabilities | 119.65M | 652.18M | 670.13M | 281.97M | 266.3M |
| Total Liabilities | 995.81M | 1.08B | 1.04B | 877.65M | 742.91M |
| Common Stock | 54K | 55K | 56K | 57K | 58K |
| Retained Earnings | 368.57M | 390.73M | 370.36M | 382.89M | 384.94M |
| Accumulated OCI | (8.41M) | (17.09M) | (13.43M) | (17.2M) | (8.85M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.15B | 1.13B | 1.19B | 1.24B | 1.23B |
| Total Debt | 541.01M | 616.74M | 614.09M | 382.55M | 204.35M |
| Net Debt | 191.96M | 286.38M | 146.12M | 13.35M | 7.83M |
Omnicell, Inc.
NASDAQ:OMCL
Intrinsic Alpha fair value
Locked
Current Price
$34.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.